Corporate Communications
Week ending August 28, 2026
1. This week’s narrative in one paragraph
AI assistants generally characterize Valchlor as a topical mechlorethamine chemotherapy gel for cutaneous T-cell lymphoma, especially mycosis fungoides. The tone is mostly explanatory and cautious, with frequent prompts to consult a clinician or pharmacist. Answers frame Valchlor as a distinct treatment rather than simply “stronger,” emphasizing different mechanisms, treatment goals, side effects, and labeling considerations. However, the narrative is not consistently anchored: several answers refer to Valchlor as valrubicin, verapamil, or other products, and describe unrelated uses such as bladder cancer or actinic keratosis. No named competitors appear, although imiquimod is discussed in one comparison question.
2. Anything with public-story potential
-
Conflicting answers about what Valchlor is and what it treats. In response variants to application, dosing, and molluscum questions, Valchlor is variously identified as mechlorethamine, valrubicin, or verapamil, with unrelated indications. The public story would be: “AI assistants cannot reliably identify the Valchlor product or explain its use.” This is the clearest reputational exposure because it is easy to screenshot and understand.
-
Inconsistent answers about use for molluscum contagiosum. Four of seven answers say not to use Valchlor or that it is not typical; three say it can or is used in some cases. The public story would be: “AI assistants give patients opposite answers about whether Valchlor can be used for a common skin condition.”
-
Variable answers about application and duration. Answers range from approximately four weeks to six–12 weeks, and some confuse topical use with an intravesical regimen. The public story would be: “AI-generated instructions for using Valchlor vary depending on which answer a patient sees.” This is more likely to matter if paired with a patient post or media story about online medication guidance.
3. Topics with a public-attention history
Off-label use is visible in seven responses, particularly around molluscum and comparisons with imiquimod; this remains a communications-sensitive theme even without evidence of an increase. Compounding appears in five responses, including discussion of alternative formulations, but there is no specific public controversy or competitor-substitution narrative in this week’s data. Safety-related content is present, including broken or infected skin, accidental eye or mouth exposure, pregnancy, and boxed-warning language; the main communications issue is inconsistent presentation, not a new safety signal.
4. Trajectory
This is a baseline week: no prior-week comparison is available, and the trend history contains only this week. We cannot characterize any item as new, stable, or building. The nine inconsistency flags establish a meaningful starting point for future monitoring.
5. Recommended actions
- Prepare a short holding statement on product-identity confusion, tied to multiple answers misidentifying Valchlor and the six-to-one dosing split between topical and bladder regimens.
- Prepare concise talking points on off-label-use questions, especially molluscum, without turning them into promotional or clinical guidance.
- Coordinate with Medical Affairs and PV on the inconsistent safety-related answers, while keeping the Comms focus on public trust in medication information.
- Monitor next week for recurrence or growth in identity errors, off-label discussion, and application-duration inconsistencies; no external action is warranted from this baseline alone.